ArticlePsychiatry (Edgmont (Pa. : Township))2008
General medical with depression drugs associated.
Article in Psychiatry (Edgmont (Pa. : Township)), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Clinical practice guideline for assessment and management of depression in India.Indian journal of psychiatry · 2026Article
- The Role of Chronic Disease Numbers in the Relationship Between Living Alone and Depression: A Four-Way Decomposition Analysis in a Cross-Sectional Study of Older Adults.Clinical interventions in aging · 2025Article
- Niosomal Bupropion: Exploring Therapeutic Frontiers through Behavioral Profiling.Pharmaceuticals (Basel, Switzerland) · 2024Article
- The Role of Genetics in the Development and Pharmacotherapy of Depression and Its Impact on Drug Discovery.International journal of molecular sciences · 2023Review
- Prevalence and factors associated with psychological distress among patients on warfarin at the Uganda Heart Institute, Mulago Hospital.BMC psychiatry · 2022Article
- Chimeric Structures in Mental Illnesses-"Magic" Molecules Specified for Complex Disorders.International journal of molecular sciences · 2022Review
- Isotretinoin and neuropsychiatric side effects: Continued vigilance is needed.Journal of affective disorders reports · 2021Article
- Pharmacist-Led Medication Evaluation Considering Pharmacogenomics and Drug-Induced Phenoconversion in the Treatment of Multiple Comorbidities: A Case Report.Medicina (Kaunas, Lithuania) · 2021Article
- Late Life Depression: The Essentials and the Essential Distinctions.Focus (American Psychiatric Publishing) · 2021Article
- Prevalence and Determinants of Long-Term Utilization of Antidepressant Drugs: A Retrospective Cohort Study.Neuropsychiatric disease and treatment · 2020Article
- Investigation of the underling mechanism of ketamine for antidepressant effects in treatment-refractory affective disorders via molecular profile analysis.Experimental and therapeutic medicine · 2019Article
- Depression in the Primary Care Setting. Reply.The New England journal of medicine · 2019Article
- Polypharmacy in an Elderly Population: Enhancing Medication Management Through the Use of Clinical Decision Support Software Platforms.Neurology and therapy · 2019Article
- Depression in the Primary Care Setting.The New England journal of medicine · 2019Review
- Psychiatric and Developmental Effects of Isotretinoin (Retinoid) Treatment for Acne Vulgaris.Current therapeutic research, clinical and experimental · 2019Review
- Is Mania the Hypertension of the Mood? Discussion of A Hypothesis.Current neuropharmacology · 2017Review
- Major depression in primary care: making the diagnosis.Singapore medical journal · 2016Article
- The bidirectional relation between psychiatric disorders with selected cardiovascular and endocrinal diseases: an Egyptian perspective.Current psychiatry reports · 2015Review
- Effects of centrally acting ACE inhibitors on the rate of cognitive decline in dementia.BMJ open · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-induced depression has been the focus of intense scrutiny by the US Food and Drug Administration and has serious clinical and medicolegal implications. "Gold standard" studies of drug-induced depression-involving randomized, placebo-controlled design and direct assessment of depressive symptoms-are lacking. Based on the available literature, our review suggests that only a few types of drugs are strongly linked with induction of depression. However, the potential for idiosyncratic reactions-not necessarily detected in large-scale studies-suggests that particular caution and careful monitoring are warranted with several types of drugs, including isotretinoin, rimonabant, and alpha interferons.
Indexed as
Identifiers
19724774PMC2729620What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.